A natural compound named forskolin has demonstrated a dual-action effect against one of the most aggressive forms of blood cancer: acute myeloid leukemia with KMT2A gene rearrangement (KMT2A-r AML). The findings of this significant study were published in the British Journal of Pharmacology.
Researchers discovered that forskolin directly inhibits the proliferation of leukemia cells. Its mechanism involves activating the PP2A enzyme and blocking the function of several crucial oncogenes, such as MYC, HOXA9, and HOXA10, which typically drive the rapid growth of cancerous cells.
Furthermore, the compound was found to enhance the efficacy of chemotherapy. When forskolin was introduced, leukemia cells became significantly more susceptible to daunorubicin, a key medication used in leukemia treatment. The underlying mechanism was unexpected: forskolin blocked the activity of P-glycoprotein 1, a protein known for pumping drugs out of cells and reducing their effectiveness. This action allowed daunorubicin to remain longer within the cells, thereby increasing its potency.
Combining forskolin with chemotherapy holds the potential to boost treatment success rates and allow for reduced doses of toxic drugs, consequently mitigating severe side effects. Experts highlight that these findings pave the way for developing gentler and more effective therapeutic regimens, potentially doubling the five-year survival rate for patients with this diagnosis within the next decade.
In a separate report from early July, scientists suggested that the mode of delivery might be a contributing factor to the development of childhood leukemia. Research indicated a slightly elevated risk of the disease in children born via planned C-sections compared to those born through natural delivery.
